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Vitiligo, a skin disorder characterized by the spontaneous destruction of melanocytes, is believed to be of
autoimmune origin. We investigated the presence and functionality of CD8þ T-cells specific for the melanocyte-
associated antigens Melan-A, gp100, tyrosinase, and TRP-2 in the blood of HLA-A2þ vitiligo patients. We
enumerated antigen-specific CD8þ T cells by major histocompatibility complex multimer staining directly
ex vivo, as well as after 9 days of in vitro stimulation and assessed IFN-g secretion by enzyme-linked
immunospot (Elispot) assay. Tyrosinase-, gp100-, or TRP-2-specific CD8þ T cells could not be identified in the
peripheral blood of individuals with vitiligo. Although Melan-A-specific T cells were detectable at levels
comparable to Flu-MP-specific T cells by multimer staining, these lymphocytes did not express the skin-homing
receptor cutaneous lymphocyte antigen, were phenotypically naı¨ve (CD45RAþ ), and were unresponsive in the
IFN-g Elispot assay, suggesting that they are unlikely to be involved in the etiopathogenesis of vitiligo.
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INTRODUCTION
Vitiligo, a skin disorder characterized by the spontaneous
destruction of melanocytes, is believed to be of autoimmune
origin (Kemp et al., 2001; Garbelli et al., 2005). Studies have
identified circulating CD8þ T cells in vitiligo subjects
specific predominantly for Melan-A/MART1 (Melan-A), but
also for tyrosinase and gp100 (Ogg et al., 1998; Lang et al.,
2001). Melanocyte-associated antigen (MAA)-specific T cells
have also been derived from biopsies of vitiligo lesions (van
den Wijngaard et al., 2000; Le Gal et al., 2001). In vitiligo,
the Melan-A-specific CD8þ T cells have been reported to be
of a memory phenotype (CD45ROþ ) and to express the skin-
homing receptor cutaneous lymphocyte antigen (CLA) (Ogg
et al., 1998), suggesting a pathogenic role for melanocyte-
specific T cells. Tyrosinase-related protein (TRP)-2 is another
MAA of interest, as murine immunization with TRP-2 can
induce skin depigmentation (Steitz et al., 2000, 2006).
Although antibodies to TRP-2 have been described in vitiligo
patient sera (Okamoto et al., 1998), T-cell responses to TRP-2
have not yet been evaluated in vitiligo. Understanding the
mechanism underlying vitiligo could aid the development of
more effective therapies and provide insights into the
etiopathogenesis of the condition.
RESULTS AND DISCUSSION
In healthy volunteers, no antigen-specific T-cell responses
to gp100, tyrosinase TRP-2, or Melan-A were detected by
IFN-g Elispot (Figure 1, open squares). All of these subjects,
however, exhibited strong Flu-MP T-cell responses. In the
vitiligo patients, we also did not observe Elispot responses to
any of the MAA, although the majority of subjects demons-
trated strong Flu-MP responses (Figure 1 closed circles, and
Table 1). These ex vivo Elispot results were confirmed by an
independent laboratory (P. Romero, Ludwig Institute for
Cancer Research).
Multimer staining to detect MAA-specific circulating
T cells in the group of vitiligo patients revealed only low or
borderline frequencies of Melan-Aþ CD8þ T cells when
evaluated by ex vivo assays (Table 1). These cells had a naı¨ve
phenotype (CD45RAþ ) and did not express CLA (Figure 2a
and b, shown for patient V0002). Melan-A responses could
be easily identified in all vitiligo subjects following expansion
by IVS (Table 1 and Figure 2c). Flu-MP-multimerþ T cells
detected in vitiligo patients could also be significantly
enriched after IVS compared with the ex vivo assay (Table 1
and Figure 2c). In contrast to Melan-A-specific T cells,
however, Flu-MP-specific T cells exhibited a memory
phenotype (CD45RA, Figure 2a, shown for patient V0005).
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We did not detect multimer-positive T cells either ex vivo or
after IVS for any of the other MAA in the vitiligo group (data
not shown).
Our results indicate that one can detect functionally active
(IFN-g secreting) Flu-MP-specific T lymphocytes of memory
type in the peripheral blood of HLA A2þ individuals with
vitiligo, whereas these patients did not exhibit functionally
active T cells specific for the four tested HLA A2.1-restricted
melanocyte differentiation antigens. Although Melan-
A-specific T cells were detectable at comparable levels to
Flu-MP-specific T cells (as shown in multimer assays by the
presence of low levels ex vivo, which could be efficiently
expanded by IVS), these cells were phenotypically and
functionally naı¨ve as indicated by their expression of
CD45RA and unresponsiveness in the IFN-g Elispot assay.
The presence of high frequencies of peripheral blood Melan-A
tetramerþ CD8 T lymphocytes in a naı¨ve stage has been
reported previously for HLA-A2þ healthy individuals
(Pittet et al., 1999, 2001). In particular, the latter study
has convincingly shown the inability of Melan-A-tetramerþ
T cells isolated from healthy donors to secrete IFN-g by both
Elispot and Cytospot assay (which assesses IFN-g production
by intracellular staining of tetramer-labeled cells). Thus, our
detection of Melan-A-specific T cells in the HLA-A2þ vitiligo
group at comparable frequencies described in healthy
individuals, including the efficient expansion upon IVS (Pittet
et al., 1999; Salio et al., 2001), suggests that the presence of
Melan-A-specific T cells is not a feature unique to vitiligo. In
addition, we found that these cells display a naı¨ve phenotype
and do not express CLA, identical to the phenotype described
in healthy donors (Ogg et al., 1998; Pittet et al., 1999, 2001;
Palermo et al., 2001), further suggesting their presence as an
epi-phenomenon. The lack of TRP-2 reactivity in multimer
and Elispot assays was an additional unexpected finding,
given the reported presence of anti-TRP antibodies in vitiligo
patients (Okamoto et al., 1998).
A limitation of our study is the evaluation of T-cell
responses to only a small panel of HLA-A2-restricted MAA,
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Figure 1. Elispot-assisted quantification of IFNc-secreting MAA-specific
and Flu-MP-specific T cells in peripheral blood of all HLA A2þ individuals
tested. Healthy individuals are shown as open squares and vitiligo patients
shown as closed circles.The threshold for detection for this ex vivo assay
defined as o50 SFCs per 106 PBMCs (horizontal line).
Table 1. Circulating Melan-A- and Flu-MP-specific
CD8+ T cells in vitiligo patients (6 subjects)
Patient ID Melan-A Flu-MP
Elispot1 Multimer2 Multimer3 Elispot1 Multimer2 Multimer3
V0001 Negative 0.02 12.7 Negative 0.01 29.8
V0002 Negative 0.08 45.1 75 0.05 46.6
V0003 Negative 0.03 2.1 115 0.03 53.4
V0005 Negative 0.08 33.7 330 0.26 65.1
V0006 Negative 0.02 27.2 Negative 0.03 11.9
V0010 Negative 0.05 34.7 205 0.29 68.4
1Number of IFN-g-producing T cells (SFCs) per 106 PBMCs; negative
responses were defined as o50 SFCs per 106 PBMCs, after subtracting
background.
2Multimer+ cells as % of enriched CD8+ T cells ex vivo.
3Multimer+ cells as % of CD8+ T cells after 9 days in vitro peptide
stimulation; average of duplicates.
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Figure 2. Multimer-assisted monitoring of Melan-A and Flu-MP-specific T cells in peripheral blood of vitiligo patients (representative plots).
(a) Comparison of phenotypes of Melan-A- and Flu-MP-specific CD8þ T cells assayed ex vivo by multimers. (b) Lack of CLA expression by Melan-A-multimerþ
T cells, analyzed ex vivo. (c) Melan-A and Flu-MP-specific T cells expanded in vitro in the presence of IL-2 for 9 days.
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which cannot rule out the involvement of T cells specific
for other MAA in the etiopathogenesis of vitiligo. It is
also possible that MAA-specific T cells may be localized
in lesional skin, leading to a potential underrepresentation
in peripheral blood. As this study did not examine
vitiligo-infiltrating lymphocytes, we cannot rule out the
existence of MAA-specific T cells in the skin. However,
preliminary studies of CD3þ lymphocytes isolated from
perilesional skin indicate only very low frequencies of
tyrosinase, gp100 and Melan-A multimerþ cells, which
could not be expanded in vitro (K. Ongenae and P. Romero,
personal communication).
In summary, in our series we fail to detect T cells in the
peripheral blood of individuals with vitiligo, which target the
tested HLA-A2-restricted epitopes of tyrosinase, gp100 or
TRP-2, and cannot confirm the presence of circulating
functionally active, CLA-expressing Melan-A2635-specific
T cells described previously.
MATERIALS AND METHODS
We investigated antigen-specific T-cell responses to four MAA
peptides in the blood of adult vitiligo patients. We enrolled patients
with active or stable generalized vitiligo of greater than 1 year
(n¼ 14), as well as healthy volunteers (n¼ 12) in a Rockefeller
University IRB-approved protocol. The Declaration of Helsinki
principles were followed and patients gave their written, informed
consent. Subjects were included in the analysis if they were
HLA-A2.1þ , which resulted in the following sized groups: healthy
volunteers (n¼ 6) and vitiligo (n¼ 6).
Blood was obtained by venipuncture and peripheral blood
mononuclear cells (PBMCs) were isolated by Ficoll–Hypaque density
centrifugation. HLA typing was performed by flow cytometry
using an mAb specific to HLA-A2 (hybridoma HB-82, ATCC,
Manassas, VA). MAA-specific T-cell responses in healthy donors
and vitiligo subjects were assessed by IFN-g enzyme linked
immunospot (Elispot) assay. PBMCs were added to wells of anti-
IFN-g antibody-coated 96-well multiscreen IP (Immobilon-P)
plates (Millipore, Billerica, MA, USA) at a concentration of
200,000 cells per well in triplicate and incubated overnight in
the presence of MAA at peptide concentrations of 10 mg ml1.
Spot-forming cells (SFCs), indicating IFN-g-secreting antigen-specific
T-cells, were averaged per well, then multiplied by 5 to report SFCs/
Million PBMCs. Results were measured in response to the following
HLA*0201-restricted MAA peptides: tyrosinase368376(370D)
(YMDGTMSQV), gp100209217 (ITDQVPFSV), Melan-A2635 (EAA-
GIGLTV), and TRP-2180188 (SVYDFFVWL). Control peptides were
influenza (Flu-MP5866,GILGFVFTL), MAGE3271279 (FLWGPRALV),
and HIV (gag7785, SLYNTVATL). Peptides were synthesized by
Genmed Synthesis (San Francisco, CA) or by the Rockefeller
University Peptide Core Facility (New York, NY).
We also performed major histocompatibility complex multimer
staining for the vitiligo group to enumerate MAA-specific CD8þ
T cells in the circulation (enriched for CD8þ cells using Milteny
MACS beads). Multimers were synthesized and validated at the
tetramer production facility, Ludwig Institute for Cancer Research
(Lausanne, Switzerland), using the same peptides as above, although
the Melan-A peptide was a modified ‘‘ELA’’ substitution (A to L at
position 27) with greater major histocompatibility complex affinity
(Valmori et al., 1998). Using fluorescent HLA-A*0201/peptide
multimers, a minimum of 50,000 magnetically sorted CD8 T cells
were acquired (up to 200,000 events) as described previously (Pittet
et al., 1999). We determined the frequency of circulating CD8þ
T cells directly ex vivo, as well as after 9 days of in vitro stimulation
(IVS) for increased assay sensitivity. For IVS, PBMCs were incubated
in duplicate in the presence of each peptide plus 100 IU ml1 IL-2 for
9 days and the results were averaged. Multimer-positive responses in
the ex vivo assay were defined asX0.05% of enriched CD8þ T cells
and in the IVS assay as X0.1% of CD8þ T cells. CD45RA and CLA
expression were also measured in the ex vivo assay.
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